After neatly wrapping up concerns over a series of Emgality ads last month, Eli Lilly is back in hot water with the FDA's Office of Prescription Drug Promotion. The FDA gave Lilly a slap on the wrist ...

Sanofi and Regeneron’s immunology blockbuster Dupixent was knocked down into second place as Eli Lilly’s diabetes medicine Trulicity took the top spot for January’s biggest TV ad spenders, according ...

Shares of Eli Lilly and Company (NYSE:LLY) dropped Thursday morning after the company announced that its diabetes treatment Mounjaro did not demonstrate superiority over Trulicity, its older GLP-1 ...

Aug 28 (Reuters) - Europe will continue to face a shortage of Eli Lilly & Co's (LLY.N), opens new tab blockbuster diabetes drug Trulicity through September, the European Medicines Agency (EMA) said on ...